Findings

What do systematic reviews say?

53 questions · 62 findings · 5 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 8.1%Low 28 · 45.2%Moderate 18 · 29%High 11 · 17.7%

Self‐monitoring of oral anticoagulation vs usual care

Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

Self‐monitoring of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).

1 finding from 1 review

Self‐monitoring and self‐management of oral anticoagulation 2016 · Cochrane Headline outcomes only
RR 0.69 [0.49, 0.97]
7 studies · 4097 participants
Moderate

Self‐monitoring of oral anticoagulation vs usual care

All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).

1 finding from 1 review

Self‐monitoring and self‐management of oral anticoagulation 2016 · Cochrane Headline outcomes only
RR 0.94 [0.78, 1.15]
3 studies · 3300 participants
Moderate

Self‐monitoring of oral anticoagulation vs usual care

Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

Self‐monitoring of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (low certainty).

1 finding from 1 review

Self‐monitoring and self‐management of oral anticoagulation 2016 · Cochrane Headline outcomes only
RR 0.9 [0.74, 1.09]
7 studies · 4038 participants
Low

Self‐monitoring of oral anticoagulation vs usual care

Minor haemorrhage · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

Self‐monitoring of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (moderate certainty).

1 finding from 1 review

Self‐monitoring and self‐management of oral anticoagulation 2016 · Cochrane Headline outcomes only
RR 1.16 [0.95, 1.42]
6 studies · 3503 participants
Moderate

self‐management of oral anticoagulation vs usual care

Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

self‐management of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).

1 finding from 1 review

Self‐monitoring and self‐management of oral anticoagulation 2016 · Cochrane Headline outcomes only
RR 0.47 [0.31, 0.7]
11 studies · 3497 participants
Moderate

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1546 participants
Very low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4865 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1546 participants
Very low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1403 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Moderate

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1542 participants
Very low

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1393 participants
Low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1403 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low